Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

12.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
6.8K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.5K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Measurement of High-Energy Reactor Antineutrinos at Daya Bay.

Physical review letters·2022
Same author

Joint Determination of Reactor Antineutrino Spectra from ^{235}U and ^{239}Pu Fission by Daya Bay and PROSPECT.

Physical review letters·2022
Same author

Improved Constraints on Sterile Neutrino Mixing from Disappearance Searches in the MINOS, MINOS+, Daya Bay, and Bugey-3 Experiments.

Physical review letters·2020
Same author

Large magnetic gap at the Dirac point in Bi<sub>2</sub>Te<sub>3</sub>/MnBi<sub>2</sub>Te<sub>4</sub> heterostructures.

Nature·2019
Same author

Extraction of the ^{235}U and ^{239}Pu Antineutrino Spectra at Daya Bay.

Physical review letters·2019
Same author

Measurement of the Electron Antineutrino Oscillation with 1958 Days of Operation at Daya Bay.

Physical review letters·2019

Related Experiment Video

Updated: Mar 9, 2026

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

7.2K

Analyzing Amyloid-β Peptide Modulation Profiles and Binding Sites of γ-Secretase Modulators.

J Trambauer1, A Fukumori2, B Kretner2

  • 1Biomedical Center (BMC), Metabolic Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany.

Methods in Enzymology
|January 10, 2017
PubMed
Summary

γ-Secretase modulators (GSMs) offer a promising therapeutic strategy for Alzheimer's disease (AD) by reducing toxic amyloid-β (Aβ) production. Unlike inhibitors, GSMs safely shift Aβ generation without harming essential substrates like Notch.

Keywords:
Amyloid β-peptideImmunoprecipitationMALDI-TOF mass spectrometryPhotoaffinity labelingSandwich immunoassayStreptavidin pull-downTris–Bicine urea SDS-PAGEγ-Secretase modulator

More Related Videos

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by &#947;-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

655
A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.7K

Related Experiment Videos

Last Updated: Mar 9, 2026

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

7.2K
Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by &#947;-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

655
A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.7K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • γ-Secretase is implicated in Alzheimer's disease (AD) pathogenesis through amyloid precursor protein (APP) cleavage.
  • Amyloid-β (Aβ) peptides, particularly Aβ42 and Aβ43, aggregate and form plaques, considered causative of AD.
  • Previous γ-secretase inhibitors failed in clinical trials due to off-target effects on substrates like Notch.

Purpose of the Study:

  • To explore the potential of γ-secretase modulators (GSMs) as a safer therapeutic approach for AD.
  • To investigate how GSMs modulate γ-secretase activity and affect Aβ peptide generation.
  • To describe methods for identifying the molecular targets of GSMs.

Main Methods:

  • Utilizing biochemical assays to assess γ-secretase activity.
  • Employing molecular biology techniques to investigate substrate processing.
  • Developing and applying methods for target identification of GSMs.

Main Results:

  • GSMs selectively shift Aβ generation from longer, aggregation-prone species (Aβ42, Aβ43) to shorter peptides.
  • GSMs preserve the cleavage of other essential substrates, such as Notch, mitigating side effects.
  • The study outlines methodologies for characterizing GSMs' mechanism of action.

Conclusions:

  • GSMs represent a promising therapeutic strategy for AD by selectively reducing toxic Aβ species.
  • GSMs offer a safer alternative to direct γ-secretase inhibitors, avoiding Notch pathway disruption.
  • Further research utilizing described methods can advance the development of GSM-based AD therapies.